N Vianelli
Overview
Explore the profile of N Vianelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M, et al.
Ann Hematol
. 2024 May;
103(7):2347-2354.
PMID: 38771499
Ropeginterferon-alfa2b (ropegIFNα2b) is a long-acting IFN formulation with broad FDA/EMA approval as a therapy of polycythemia vera (PV) with no symptomatic splenomegaly. There is currently lack of information on the...
2.
Palandri F, Auteri G, Abruzzese E, Caocci G, Bonifacio M, Mendicino F, et al.
Ann Hematol
. 2024 Mar;
103(6):1931-1940.
PMID: 38478023
Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study...
3.
De Stefano V, Vannucchi A, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, et al.
Blood Cancer J
. 2016 Nov;
6(11):e493.
PMID: 27813534
We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and...
4.
Porta C, Buggia I, Bonomi I, Gugliotta L, Vianelli N, Centurioni R, et al.
Hematology
. 2016 Jul;
1(3):239-46.
PMID: 27406618
The enhanced platelet aggregation and thrombosis occurring in TTP is probably due to an unbalance between agents insulting endothelial integrity and natural antithrombotic factors, such as NO. Using a sensitive...
5.
De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi M, et al.
Leukemia
. 2016 Apr;
30(10):2032-2038.
PMID: 27113812
The optimal duration of treatment with vitamin K antagonists (VKA) after venous thromboembolism (VTE) in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) is uncertain. To tackle this issue, we retrospectively studied...
6.
Polverelli N, Catani L, Vianelli N, Baccarani M, Cavo M, Palandri F
Ann Hematol
. 2015 May;
94(9):1585-7.
PMID: 25975976
No abstract available.
7.
Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, et al.
Leukemia
. 2015 Mar;
29(6):1344-9.
PMID: 25801912
We investigated the influence of molecular status on disease characteristics and clinical outcome in young patients (⩽ 40 years) with World Health Organization (WHO)-defined essential thrombocythemia (ET) or early/prefibrotic primary...
8.
Trecarichi E, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, et al.
Clin Microbiol Infect
. 2015 Jan;
21(4):337-43.
PMID: 25595706
A prospective cohort study was conducted in nine hematology wards at tertiary care centres or at university hospitals located throughout Italy from January 2009 to December 2012. All of the...
9.
Pagano L, Caira M, Tumbarello M, Fanci R, Garzia M, Vianelli N, et al.
Ann Hematol
. 2011 Nov;
91(5):767-774.
PMID: 22124621
The Hema e-Chart prospectively collected data on febrile events (FEs) in hematological malignancy patients (HMs). The aim of the study was to assess the number, causes and outcome of HM-related...
10.
Vigna E, De Vivo A, Gentile M, Morelli R, Lucia E, Mazzone C, et al.
Transpl Infect Dis
. 2010 Jun;
12(5):428-31.
PMID: 20534035
Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and...